BNT111, a melanoma mRNA-lipoplex vaccine targeting four TAAs (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE), has already demonstrated safety and immunogenicity in the phase I clinical trial, Lipo-MERIT for advanced melanoma patients [226]. Here, MAGEA3 is linked to melanoma.